Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMikkael A. SekeresAYAylin YücelDMDimana Miteva

Discussion

Loading...

Member takes

Overview

Observational study reports clinical outcomes of luspatercept for anemia in myelodysplastic syndromes, indicating effective management strategies.

Key Points

  • To describe the real-world treatment patterns and outcomes of luspatercept in patients with myelodysplastic syndromes.
  • Retrospective observational study using Flatiron Health electronic record database.
  • Included patients ≥18 years diagnosed with MDS after January 1, 2020, with known ring sideroblast status.
  • Outcomes evaluated were transfusion independence and modified erythroid hematologic improvement.
  • 61.5% of transfusion-dependent patients achieved transfusion independence after luspatercept treatment.
  • 50.9% of patients had a modified erythroid hematologic improvement response.
  • 27.5% of patients required dose escalation during treatment.

Cite This Study

Sekeres et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df80https://doi.org/10.1182/blood-2025-5638
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US2025 · 1 citations
  2. 2Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa2024 · 7 citations
  3. 3Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.2024 · 2 citations
  4. 4Luspatercept for the treatment of myelodysplastic syndrome: A retrospective cohort study utilizing trinetx2025
  5. 5The efficacy and safety of luspatercept in patients with low-blasts myelodysplastic neoplasms in real world2025